Goldfine, Andrew et al "Results of a Phase 1 Dose-Ranging Trial, and Design of a Phase 2 Trial, of K0706, a Novel C-Abl Tyrosine Kinase Inhibitor for Parkinson’s Disease. (P2.8-047)." Neurology 92.15 Supplement (2019): P2.8-047. Web. 28 Jan. 2022.